Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cross-Linking of Keratoprosthesis Carrier Tissue
NCT02863809Phase 2Completed
- Start
- Mar 2017
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of riboflavin in pitted keratolysis (PK) (2 arms). Primary endpoint: Time From Surgery to Device Loss or Replacement at 2 years. Started Mar 2017; status: completed.
02
Drugs
riboflavin
03
Conditions
pitted keratolysis (PK)
Beyond the preview
Go deeper on NCT02863809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02863809.